×
About 28,378 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  8,342 results

The Nutritional Trajectory of Children with Acute Lymphoblastic Leukemia: A 10-Year Fol...
https://doi.org/10.1080/01635581.2022.2152194
Nutrition and Cancer; Joseph LL, Srinivasan HN et. al.

Nov 30th, 2022 - Survivors of childhood acute lymphoblastic leukemia (ALL) are vulnerable to late adverse events such as obesity and an associated metabolic syndrome. Children treated for ALL from 2002 to 2012 were included. BMI was calculated at diagnosis, end of...

Clinical characteristics and risk factors for bloodstream infections in children with c...
https://doi.org/10.2174/1871525721666221125093836
Cardiovascular & Hematological Agents in Medicinal Chemis... Bangeas A, Protonotariou E et. al.

Nov 29th, 2022 - Infections are a major cause of morbidity and mortality in children with haematologic malignancies and solid tumors as well as those undergoing hematopoietic stem cell transplantation (HSCT). The purpose of our study was to record the epidemiologi...

Evolution and optimization of therapies for acute lymphoblastic leukemia in infants.
https://doi.org/10.1007/s12185-022-03502-w
International Journal of Hematology; Tomizawa D

Nov 29th, 2022 - Acute lymphoblastic leukemia (ALL) in infants accounts for less than 5% of pediatric ALL and is biologically and clinically unique. Approximately 70% to 80% of cases present as an aggressive leukemia with KMT2A gene rearrangement (KMT2A-r), which ...

Mortality Among Pediatric Patients With Acute Lymphoblastic Leukemia in Sweden From 198...
https://doi.org/10.1001/jamanetworkopen.2022.43857
JAMA Network Open; Björk-Eriksson T, Boström M et. al.

Nov 29th, 2022 - Acute lymphoblastic leukemia (ALL) constitutes 20% to 30% of all pediatric cancers. The 5-year overall survival among pediatric patients with ALL in high-income countries such as Sweden is currently more than 90%, but long-term unselected nationwi...

Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3...
https://doi.org/10.1016/j.blre.2022.101031
Blood Reviews; Raiola AM, Angelucci E et. al.

Nov 27th, 2022 - We report 634 patients who underwent unmanipulated haploidentical (HAPLO) bone marrow transplantation (BMT) in two Centers. The diagnosis was acute myeloid leukemia (AML) (n = 251), acute lymphoblastic leukemia (ALL)(n = 107), myelodysplastic synd...

see more →

Guidelines  4 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

see more →

Drugs  130 results see all →

Clinicaltrials.gov  951 results

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03739814

Oct 14th, 2022 - PRIMARY OBJECTIVES: I. To confirm tolerability of the combination regimen of inotuzumab ozogamicin followed by blinatumomab. II. To estimate the 1-year event-free survival of older, transplant-ineligible patients with newly diagnosed, Philadelphia...

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
https://clinicaltrials.gov/ct2/show/NCT02828358

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the tolerability of azacitidine in addition to Interfant-06 standard chemotherapy in infants with newly diagnosed acute lymphoblastic leukemia (ALL) with KMT2A gene rearrangement (KMT2A-R). SECONDARY OBJECTIVE: I....

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
https://clinicaltrials.gov/ct2/show/NCT03531814

Oct 14th, 2022 - Background: Neurofibromatosis type 1 (NF1) is a genetic disorder that affects approximately 1 in 3,500 individuals and is associated with a broad variety of symptoms and physical findings. Plexiform neurofibromas (PN) are histologically benign tum...

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT02315612

Oct 14th, 2022 - Background: Adoptive cellular therapy with T cells genetically modified using viral-based vectors to express chimeric antigen receptors targeting the CD19 molecule have demonstrated dramatic clinical responses in patients with acute lymphoblastic ...

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
https://clinicaltrials.gov/ct2/show/NCT02390752

Oct 14th, 2022 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

see more →

News  1,916 results

Lung Screening Saves Lives; Clues to Hyperprogression; Bacteria Foil Immunotherapy
https://www.medpagetoday.com/hematologyoncology/lungcancer/101912

Nov 25th, 2022 - Diagnosis of early-stage lung cancer with low-dose CT screening was associated with significant improvement in long-term survival. (Mount Sinai, Radiological Society of North America) Researchers have discovered how cancer immunotherapy sometimes ...

Dr. Jabbour on MRD Testing in B-ALL
https://www.onclive.com/view/dr-jabbour-on-mrd-testing-in-b-all

Nov 23rd, 2022 - Elias Jabbour, MD, professor, the Department of Leukemia, the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of testing for minimal residual disease (MRD) when determining optimal treatment...

FDA Approves Additional Dosing Schedule for Rylaze in ALL and LBL
https://www.onclive.com/view/fda-approves-additional-intramuscular-dosing-schedule-for-rylaze-in-all-and-lbl

Nov 18th, 2022 - The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday (MWF) intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).1 In June 2021, Rylaze was approved for use a...

Ponatinib Provides Higher Rate of MRD-negative CR Vs Imatinib in Newly Diagnosed Ph+ ALL
https://www.onclive.com/view/ponatinib-provides-higher-rate-of-mrd-negative-cr-vs-imatinib-in-newly-diagnosed-ph-all

Nov 17th, 2022 - Ponatinib (Iclusig) plus reduced-intensity chemotherapy produced a higher rate of minimal residual disease (MRD)–negative complete remission compared with imatinib (Gleevec) in patients with newly diagnosed Philadelphia chromosome (Ph)–positive ac...

CAR Therapy Era Moves Forward With Much Excitement, Lingering Questions
https://www.onclive.com/view/car-therapy-era-moves-forward-with-much-excitement-lingering-questions

Nov 16th, 2022 - CAR T-cell therapies have generated considerable enthusiasm in the oncology community since the first FDA approval in 2017. From a clinical standpoint, these therapies have significantly improved outcomes in disease settings where the outlook for ...

see more →

Patient Education  8 results see all →